DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,581,075 | +2.8% | 14,434 | -0.6% | 0.48% | +13.9% |
| Q2 2023 | $3,484,080 | -33.0% | 14,517 | -29.6% | 0.42% | -36.0% |
| Q1 2023 | $5,198,829 | -11.5% | 20,627 | -6.8% | 0.66% | -15.6% |
| Q4 2022 | $5,876,399 | -2.0% | 22,140 | -4.7% | 0.79% | -2.4% |
| Q3 2022 | $5,997,000 | -27.2% | 23,220 | -28.5% | 0.81% | -11.9% |
| Q2 2022 | $8,238,000 | -7.6% | 32,496 | +6.9% | 0.92% | +8.4% |
| Q1 2022 | $8,915,000 | -10.9% | 30,393 | -0.1% | 0.84% | +7.0% |
| Q4 2021 | $10,009,000 | +13.7% | 30,421 | +5.2% | 0.79% | +7.3% |
| Q3 2021 | $8,806,000 | -6.2% | 28,925 | -17.3% | 0.74% | -2.9% |
| Q2 2021 | $9,391,000 | +39.1% | 34,993 | +16.7% | 0.76% | +27.7% |
| Q1 2021 | $6,749,000 | +35.0% | 29,984 | +33.2% | 0.59% | +39.2% |
| Q4 2020 | $5,001,000 | -16.6% | 22,512 | -19.1% | 0.43% | -15.6% |
| Q3 2020 | $5,994,000 | -26.0% | 27,838 | -39.2% | 0.50% | -29.5% |
| Q2 2020 | $8,100,000 | +119.1% | 45,806 | +71.5% | 0.72% | +64.2% |
| Q1 2020 | $3,697,000 | +54.3% | 26,712 | +71.1% | 0.44% | +93.8% |
| Q4 2019 | $2,396,000 | -79.2% | 15,614 | -80.5% | 0.22% | -74.7% |
| Q3 2019 | $11,536,000 | +1.7% | 79,871 | +0.7% | 0.89% | +6.2% |
| Q2 2019 | $11,341,000 | -23.9% | 79,349 | -29.7% | 0.84% | -23.2% |
| Q1 2019 | $14,894,000 | +28.0% | 112,819 | 0.0% | 1.09% | -0.5% |
| Q4 2018 | $11,634,000 | -5.3% | 112,819 | -0.3% | 1.09% | +14.1% |
| Q3 2018 | $12,291,000 | +70.2% | 113,115 | +54.5% | 0.96% | +92.0% |
| Q2 2018 | $7,223,000 | +19963.9% | 73,194 | +16961.5% | 0.50% | +12375.0% |
| Q2 2017 | $36,000 | -2.7% | 429 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $37,000 | +12.1% | 429 | 0.0% | 0.00% | +33.3% |
| Q4 2016 | $33,000 | -2.9% | 429 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $34,000 | -20.9% | 429 | 0.0% | 0.00% | -25.0% |
| Q2 2016 | $43,000 | +2.4% | 429 | -2.5% | 0.00% | 0.0% |
| Q1 2016 | $42,000 | +13.5% | 440 | +10.0% | 0.00% | 0.0% |
| Q4 2015 | $37,000 | +8.8% | 400 | 0.0% | 0.00% | -20.0% |
| Q3 2015 | $34,000 | 0.0% | 400 | 0.0% | 0.01% | +25.0% |
| Q2 2015 | $34,000 | 0.0% | 400 | 0.0% | 0.00% | -20.0% |
| Q1 2015 | $34,000 | 0.0% | 400 | 0.0% | 0.01% | 0.0% |
| Q4 2014 | $34,000 | +13.3% | 400 | 0.0% | 0.01% | +25.0% |
| Q3 2014 | $30,000 | -3.2% | 400 | 0.0% | 0.00% | 0.0% |
| Q2 2014 | $31,000 | +3.3% | 400 | 0.0% | 0.00% | 0.0% |
| Q1 2014 | $30,000 | -3.2% | 400 | 0.0% | 0.00% | -20.0% |
| Q4 2013 | $31,000 | +10.7% | 400 | 0.0% | 0.01% | +25.0% |
| Q3 2013 | $28,000 | +12.0% | 400 | 0.0% | 0.00% | 0.0% |
| Q2 2013 | $25,000 | – | 400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |